U.S. Logistics Stock News

Telephone and Data Systems (TDS) just rewired its main credit agreement, extending the maturity date, stripping out certain SOFR interest add ons, and opening up an extra $300 million of secured and unsecured borrowing capacity. See our latest analysis for Telephone and Data Systems. The refinancing lands at a time when TDS’s share price has quietly rebuilt confidence, with an 11.05% year to date share price return and a striking 308.65% three year total shareholder return. This points to...

Simon Property Group (SPG) just drew fresh attention after Director Randall Lewis bought more shares, extending a steady streak of insider buying. Together with upbeat Taubman integration commentary, this is reshaping how investors are sizing up the REIT. See our latest analysis for Simon Property Group. Against this backdrop, Simon’s share price has quietly trended higher, with a solid year to date share price return and an even stronger multiyear total shareholder return suggesting momentum...

Impinj (PI) just cleared a key hurdle in its third quarter, beating earnings and revenue expectations while rolling out new Gen2X features designed to tackle counterfeiting and messy tag data across large enterprise deployments. See our latest analysis for Impinj. The upbeat quarter appears to be breathing life back into the story, with a 1 month share price return of nearly 15% helping offset a weaker 3 month patch and backing up a 5 year total shareholder return near 291%. This suggests...

NorthWestern Energy Group (NWE) has quietly outpaced many utility peers this year, with the stock up about 31% over the past year and roughly 24% year to date, catching income-focused investors attention. See our latest analysis for NorthWestern Energy Group. The latest leg higher has been driven more by a gradual shift in risk perception than by any single headline. The 90 day share price return of 17.23 percent and the 1 year total shareholder return of 31.10 percent suggest that momentum...

Ligand Pharmaceuticals (LGND) just put numbers around its 2026 outlook, projecting total revenue between $245 million and $285 million, with the bulk expected from royalty streams rather than product or contract sales. See our latest analysis for Ligand Pharmaceuticals. That forward look seems to be resonating with investors, with the share price now at $194.59 and a strong year to date share price return of 79.48 percent alongside a hefty 3 year total shareholder return of 190.30 percent,...

Butterfly Network (BFLY) is back on traders radar after a three way catalyst: a fresh licensing and co development deal with Midjourney, a director share purchase, and the launch of its Compass AI platform. See our latest analysis for Butterfly Network. Those catalysts have arrived against a backdrop of a sharp turnaround in sentiment. Butterfly’s 30 day share price return of 60.9 percent and 90 day gain of 67.7 percent contrast with a still modest 1 year total shareholder return of 1.6...

B. Riley Financial (RILY) just swung from a huge loss to solid profitability in its latest second quarter report, with revenue more than doubling and earnings per share flipping sharply back into positive territory. See our latest analysis for B. Riley Financial. The strong earnings rebound comes after a volatile stretch, with a sharp 1 day share price return of minus 17.5 percent and a 90 day share price return of minus 34.1 percent. The 3 year total shareholder return of minus 84.4 percent...

DiDi Global (OTCPK:DIDI.Y) is back in focus after launching 24/7 fully unmanned robotaxi trials in Guangzhou, raising fresh capital for its self-driving arm, completing a major buyback, and nearing closure on a sizeable U.S. IPO lawsuit settlement. See our latest analysis for DiDi Global. Despite the legal overhang easing and the robotaxi push signalling long term growth ambitions, DiDi Global’s 30 day share price return of 3.18 percent contrasts with a still weak 90 day share price return of...

CorMedix (CRMD) has quietly delivered a strong year so far, and investors are starting to ask whether the recent share performance lines up with the company’s growth profile and risk-reward trade off. See our latest analysis for CorMedix. With the share price now at $11.45, CorMedix has seen a punchy year to date, with a 39.29% year to date share price return and a standout 3 year total shareholder return of 189.87%. This suggests momentum has been building as investors reassess its growth...

Recently, BofA Securities highlighted The Cigna Group’s exposure to commercial health insurance and its scaled pharmaceutical platform, while Levi & Korsinsky began investigating potential federal securities law violations following Cigna’s disclosure of a higher Healthcare medical cost ratio that could pressure future profitability. This combination of optimism around pharmacy-driven earnings growth and scrutiny of rising medical costs underscores the tension between Cigna’s long-term...

Leidos Holdings (LDOS) just made a strategically interesting move, naming AI veteran Theodore Ted Tanner Jr. as its next chief technology officer. Investors are already asking what this could mean for the stock. See our latest analysis for Leidos Holdings. That AI focused CTO hire lands at an interesting moment, because while the 1 month share price return is slightly negative, the year to date share price return of 26.6 percent and a three year total shareholder return near 79.5 percent show...

NCR Voyix recently reported that it has retained its No. 1 global position in POS software installations across retail, reclaimed the top spot in new restaurant deployments, and reinforced its leadership in Grocery+ and convenience sectors. Alongside this industry leadership, the company’s latest quarterly results showed stronger recurring software and services revenue with improved profitability margins, reflecting progress in its platform-led, AI-enabled digital commerce strategy. Now,...

BioCryst Pharmaceuticals (BCRX) just picked up a meaningful catalyst, with the FDA clearing an oral pellet version of Orladeyo for children aged 2 to under 12 with hereditary angioedema, opening a newly addressable niche. See our latest analysis for BioCryst Pharmaceuticals. Despite this catalyst, BioCryst’s 1 year total shareholder return of around minus 2 percent and a 3 month share price return of roughly minus 10 percent suggest momentum has been fading, even as management pursues the...

Range Resources (RRC) just extended its streak of outperforming earnings expectations, backed by effective natural gas hedging that is helping smooth out commodity price swings and, in turn, lifting investor confidence in the story. See our latest analysis for Range Resources. Even after today’s 1 day share price return of 2.82 percent, Range’s stock is still down on a 1 month share price basis. However, its 5 year total shareholder return of 399.01 percent shows the longer term momentum...

SharpLink Gaming, Inc. recently completed a planned leadership transition appointing Joseph Chalom as CEO, while expanding its institutional-grade Ethereum treasury platform by more than doubling its ETH holdings and updating corporate bylaws. By increasing institutional ownership to over 30% and emphasizing Ethereum treasury management, the company is repositioning itself as a specialized, crypto-focused treasury operator within the broader digital asset ecosystem. Next, we’ll examine how...

Syndax Pharmaceuticals (SNDX) is back on traders radar after showcasing fresh data on its FDA approved cancer drugs Revuforj and Niktimvo at the high profile ASH hematology meeting in Orlando. See our latest analysis for Syndax Pharmaceuticals. The momentum around these ASH updates lines up with a strong run in the stock, with Syndax delivering a roughly 44% year to date share price return and a 59% total shareholder return over the last year, even as multi year total shareholder returns...

Expedia Group (EXPE) is back on investors radar after a stronger than expected third quarter, where earnings and demand outpaced forecasts and helped drive a 17.6% jump in the stock over the past month. See our latest analysis for Expedia Group. That surge has capped a strong run, with a roughly 16% 30 day share price return and a robust 1 year total shareholder return of about 62%, suggesting momentum is clearly building as investors reassess Expedia Group’s growth prospects and perceived...

Nasdaq, Inc. recently moved to extend U.S. equity trading to 23 hours a day on its venues, filing with the SEC for an additional overnight session and outlining operational readiness for the expanded schedule by 2026. This push toward near-continuous trading highlights Nasdaq’s effort to reshape access to U.S. markets, particularly for global and after-hours investors, while reinforcing its identity as a technology-driven market operator. We’ll now explore how Nasdaq’s 23-hour trading push...

Veralto (VLTO) just gave income investors something to chew on, with its board approving an 18% bump to the quarterly dividend. The payout is now set at 0.13 dollars per share and scheduled for payment in late January. See our latest analysis for Veralto. The move comes as Veralto’s share price sits around 100.05 dollars, with a modest positive 30 day share price return but a weaker 1 year total shareholder return. This suggests momentum is still rebuilding as investors reassess its growth...

Medical Properties Trust (MPW) just raised its quarterly dividend by more than 12%, while signing a new lease for six California hospitals, a one two punch aimed at calming nerves around cash flow and tenant risk. See our latest analysis for Medical Properties Trust. Even with a choppy patch that saw a 7 day share price return of minus 9.26 percent, Medical Properties Trust still reports a year to date share price return of 24.38 percent and a 1 year total shareholder return of 36.19 percent...

Ocular Therapeutix (OCUL) just sped up the playbook for its lead eye drug by planning to file an FDA application for AXPAXLI in wet AMD based on positive year one SOL-1 Phase 3 data. See our latest analysis for Ocular Therapeutix. The pivot to an earlier NDA comes as Ocular Therapeutix trades at $13.72, with a 1 month share price return of 16.67 percent and a year to date share price return of 56.98 percent, while its 3 year total shareholder return of 395.31 percent signals strong long term...

SS Innovations International (SSII) just hit a key milestone by filing a 510(k) submission with the FDA for its SSi Mantra surgical robot, aiming for faster, potentially lower cost entry into the US market. See our latest analysis for SS Innovations International. That progress comes after a choppy run, with a 1 day share price return of 6.7 percent and a 1 year total shareholder return of 17.4 percent suggesting momentum is starting to rebuild from a lower base. If this kind of medtech story...

CBRE Group (CBRE) is back in the spotlight after a string of upbeat analyst calls and fresh leadership moves, prompting investors to revisit how its evolving business mix might influence performance in 2026. See our latest analysis for CBRE Group. Those leadership promotions and the Pearce Services acquisition are landing against a solid backdrop, with a roughly 23 percent year to date share price return and a powerful five year total shareholder return of about 155 percent, suggesting...

Earlier in December 2025, GlaxoSmithKline notified IDEAYA Biosciences that it will terminate their 2020 collaboration and license agreement, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA within about 90 days. This shift hands IDEAYA full control of two oncology assets while the company maintains its guidance that cash resources should last into 2030. Next, we’ll examine how GSK’s exit from the collaboration reshapes IDEAYA’s investment narrative,...